Candel Therapeutics (CADL) News
NASDAQ: CADLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
9.94+0.28 (+2.90%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CADL news summary
We found 3 recent headlines mentioning Candel Therapeutics (CADL): 0 in the past week and 2 in the past 30 days, most often from Nasdaq. For price context, CADL is up 2.90% at $9.94. The most recent story, "The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux", was published by Nasdaq on Sep 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Candel Therapeutics headlines
- The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and JanuxProstate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.NasdaqNVS, PFE, JANX, CADL
- 4 Prostate Cancer Drug Stocks to Watch During Awareness MonthPfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.NasdaqNVS, PFE, JANX, CADL
- Biotech Stocks At 52-Week Highs - NEO, BLSM, RVMD, ORMP, CADL(RTTNews) - The following biotech stocks reached a 52-week high on August 27, 2026, driven by key catalysts like various regulatory milestones.NasdaqBLSM, CADL, NEO, ORMP